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Purpose: Oxaliplatin is a third-generation platinum compound, and it has no nephrotoxicity and has reduced bone mar-
row toxicity. Cancer cells that are resistant to cisplatin are sensitive to oxaliplatin. Oxaliplatin is used widely for the treat-
ment of colon cancers. Recently, oxaliplatin was reported to inhibit the expression of survivin, which protects cell apopto-
sis. However, there are no reports on the expressions of survivin variants and the changes in intracellular localization of 
survivin in cancer cells. We studied the expression of survivin caused by oxaliplatin in HCT116 colon cancer cells, and we 
observed the localization of survivin in the mitotic phase. 
Methods: We treated the HCT116 colon cancer cells with 2.0 µM of oxaliplatin, and we studied the expressions of survivin 
protein, and survivin mRNA variants, as well as the changes in intracellular localization, by using the Western blot method, 
RT-PCR, immunocytochemistry, and flowcytometry.
Results: Oxaliplatin inhibits the expression of the survivin protein and survivin mRNA in HCT116 colon cancer cells. The 
expression of the survivin-2B variants, which have no antiapoptotic activity but control  cell mitosis by localization on a 
microtubule, is reduced continuously 2 days after treatment with oxaliplatin. In immunocytochemistry, expression of sur-
vivin in the cytoplasm is reduced and especially is not expressed in microtubules and contractile rings.
Conclusion: One of the mechanisms of oxaliplatin is to inhibit the expression of and to change the localization of survivin. 
Based on these results, we suggest that changes in the expression of survivin variants and in their localization are two effects 
of oxaliplatin.
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Survivin is a type of inhibitor of apoptosis (IAP) protein that 
has the size of 16 kD and helps repress apoptosis. There are three 
different types of survivin with alternative splicing variants: 
wild-type survivin, survivin-2B (with duplicated 2nd axon), 
and survivin-ΔEx3 (with missing 3rd axon). These variations 
are known to have different functions. Generally, survivin-ΔEx3 
contains the apoptosis repressing function, but survivin-2B is 
known to have lost the apoptosis repressing function [2]. In 
addition, it was revealed that the 3 different genes of survivin 
exist in different intracellular location of different cells. How-
ever, the functions of each survivin in cancer are not yet dis-
covered [3].
Because cisplatin and carboplatin, platinum compound drugs, 
are less effective to colon cancer, they are administrated either 
singularly or in combination with 5-fluorouracil (5-FU) and 
shows approximately 20% response [4]. Oxaliplatin is a drug 
based on 3rd generation platinum compound which was de-
veloped after the discovery of cisplatin and carboplatin. Oxali-
platin was reported to have antitumor effect on cell strains that 
INTRODUCTION
The incidence of colon cancer ranks 4th among males and 3rd 
among females in Korea. Ninety percent of the patients with 
colon cancer are cured through surgical excision, but approxi-
mately half of the patients experience relapse or metastasis to 
other organs after the treatment [1]. Relapsing colon cancer is 
treated with anticancer agent primarily, but the patient gains 
tolerance to specific drugs during treatment.
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are resistant to cisplatin and carboplatin [5]. Acting mecha-
nism why oxaliplatin shows stronger cytotoxicity to cancer 
cell that has resistance to the other platinum compound drugs 
and why it is more effective when combined with other anti-
cancer drugs are not known [6]. However, repressing expres-
sion of survivin that suppress the apoptosis was reported to be 
one of the mechanisms of the oxaliplatin [7].
The authors of this research focused on oxaliplatin’s effect on 
the change of expression of survivin variants and whether ox-
aliplatin shows cytotoxicity by measuring change of expres-
sion of survivin protein and each variants of survivin mRNA.
METHODS 
Optimum oxaliplatin concentration
Oxaliplatin was donated by Sanofi-Synthelabo Korea (Seoul, 
Korea), and the optimum concentration of oxaliplatin was de-
termined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carbo-
xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
method. One-tenth, 0.2, 0.5, 1.0, 2.0, 5.0, and 10 μM of oxali-
platin were each added to separate HCT116 colon cancer cell 
strain samples and were cultured for 48 hours. Fresh culture 
fluid containing corresponding amounts of oxaliplatin was re-
placed each day, and after 48 hours after culture MTS reagent 
was added to the cells. The mixtures were settled for 2 hours. 
Cytotoxicity data were collected by measuring the optical density 
with an enzyme linked immunosorbent assay (ELISA) reader.
Survivin protein expression from the HCT116 colon cancer 
cell strain
Oxaliplatin was diluted to 2.0 μM and was added to the HCT116 
colon cancer cell strain, and the samples were cultured for 1, 
2, and 3 days. Fresh culture media containing corresponding 
amounts oxaliplatin were used each day. After 48 hours, cells 
were dissolved in cell lysis buffer solution to extract the pro-
tein. Fifty μg of protein was separated through electrophoresis 
in 3% polyacrylamide gel. This protein was transferred into 
polyvinylidene fluoride (PVDF), a Western blot was executed 
with a specific survivin antibody (anti-hSurvivin, R&D Sys-
tems, polyclonal, Cat. NO. AF886, Minneapolis, MN, USA), 
and reacted bands were detected with an image analyzer (LAS-
2000, Fuji Film, Tokyo, Japan).
Expression of a survivin mRNA variant
Two μM of oxaliplatin was added to the HCT116 colon cancer 
cell strain and was cultured for 1, 2, and 3 days. Then, Trizol 
reagent (Life Technologies, Rockville, MD, USA) was used to 
extract total RNA. Cells that were cultured were dissolved in   
1 mL of cold Trizol solution and lysed. Then, they went through 
the centrifuge at 12,000 g at 4°C for 10 minutes, and the super-
natant was moved into a new eppendorf tube and was then 
settled at room temperature for 5 minutes. Chloroform, 200 
μL, was added, thoroughly agitated for 15 seconds, and cen-
trifuged at 12,000 g at 4°C for 15 minutes after being settled 
for 3 minutes at room temperature. Supernatant-containing 
RNA was carefully moved to a new eppendorf tube, and 500 
μL of isopropyl alcohol was added and centrifuged at 12,000 g 
at 4°C for 10 minutes after being settled at room temperature 
for 10 minutes. Supernatant was removed after checking the 
presence of RNA clusters, and 1 mL of 75% ethanol was added 
to clean it. Then, it was centrifuged at 7,500 g at 4°C for 5 min-
utes, ethanol was removed, and the RNA was obtained after 
drying it in the air for 15 minutes. This RNA was dissolved in 
secondary distilled water that was treated with diethyl pyro-
carbonate (DEPC, Sigma Chemical Co. St Louis, MO, USA), 
and the concentration of RNA was measured with a spectro-
photometer measuring the optical density at 260/ 280 nm. The 
separated RNA was stored at -80°C.
In creating the cDNA, 2 μL of Oligo dT (Promega, Madison, 
WI, USA) and secondary distilled water that was treated with 
DEPC were added to 5 μg/μL of the RNA obtained from the 
HCT116 colon cancer cell strain until the mixture was 10 μL. 
Then, a fixation reaction was allowed to occur for 10 minutes 
at 70°C, the mixture was then cooled with ice for 10 minutes, 
and a master mix (5 × first strand buffer, 4 μL; 0.1 M DTT, 2 μL; 
2.5 M dNTP, 2 μL; RNase inhibitor, 1 μL) was added. The mix-
ture was reacted for 2 minutes at 42°C, 1 μL of reverse tran-
scriptase (superscript II [Life Technologies] was added, and 
the mixture was reacted again for 50 minutes at 42°C and 15 
minutes at 70°C to finally obtain the cDNA. Secondary distilled 
water without nuclease, 36.5 μL, and 5 μL of master mix (10 × 
buffer [500 mM KCl, 100 mM Tris-HCl [pH 8.3], 15 mM MgCl2]), 
4 μL of dNTP, 1 μL of primer sense, 1 μL of primer antisense, 
and 0.5 μL of Taq DNA polymerase (TaKaRa Taq
TM, Takara, 
Shiga, Japan) were added to 2 μL of cDNA. Then, the mixture 
Table 1. Primers for RT-PCR for survivin and its variants 
Forward primer Reverse primer
Survivin-1 5´AGCCCTTTCTCAAGGACCAC3´ 5´GCACTTTCTTCGCAGTTTCC3´
Survivin  5´-CCACCGCATCTCTACATTCA-3´ 5´-TATGTTCCTCTATGGGGTCG-3´
Survivin-2B  5´-CCACCGCATCTCTACATTCA-3´ 5´-AGTGCTGGTATTACAGGCGT-3´
Survivin-∆EX3  5´-CCACCGCATCTCTACATTCA-3´ 5´-TTTCCTTTGCATGGGGTC-3´
G6PDH 5´-TGGACCTGACCTACGGCAACAGATA-3´ 5´-GCCCTCATACTGGAAACCC-3´Journal of the Korean Society of
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was placed in a DNA thermal cycler (GeneAmp
®PCR system 
9700, Applied Biosystems, Foster City, CA, UAS) for 2 minutes 
at 94°C, 1 minutes (denaturing) at 94°C, 1 minutes (annealing) 
at 60°C, and 1 minutes (extension) at 72°C. Under the condi-
tions of PCR, the process was repeated 28 times to amplify 
the reaction. After the PCR reaction, electrophoresis was exe-
cuted in 1.5% agarose gel, and GAPDH was modified by using 
the same method. The primer for survivin-splicing variants is 
shown in Table 1 [8].
RESULTS
Optimum oxaliplatin concentration measurement
In order to find the optimum concentration of oxaliplatin, the 
cytotoxicity of oxaliplatin for the HCT116 colon cancer cell 
strain was measured using the MTS method. The IC50 concen-
tration was 2.0 μM in oxaliplatin, which showed the cytotox-
icity to be approximately 50% of the cells (Fig. 1). Forty-eight 
hours after each concentration of oxaliplatin had been added 
to the HCT116 colon cancer cell strain, the cultured cells were 
observed through a phase-contrast microscope (Fig. 2). When 
compared with the control group (no oxaliplatin added), the 
culture with a 1.0 μM concentration of oxaliplatin began to 
show a reduced cell count; cultures with 5.0 μM or higher con-
centrations showed noticeable reductions in cell count, and 
the cells were also deformed. Therefore, a 2.0 μM dose oxali-
platin was used in all the experiment because it was consid-
ered to be the most appropriate dose. 
Fig. 1. Cytotoxi city of oxaliplatin for HCT116 colon cancer cells, as 
determined by using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carbo-
xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) method. 
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Fig. 2. Survivin protein expression after incubation with 2 μM of ox-
aliplatin for 1-3 days. 
Fig. 3. Phase contrast images of HCT116 colon cancer cells after incubation with various concentration of oxaliplatin for 48 hours. 
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Fig. 4. Survivin mRNA 
expression in HCT116 
colon cancer cells when 
using survivin variant-
specific primers. Journal of the Korean Society of
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Expression change in survivin protein caused by oxaliplatin
Two μM of oxaliplatin was added to the HCT116 colon cancer 
cell strain and the culturing results were collected after three 
days. Survivin protein expression was reduced 1 day after the 
oxaliplatin was added, and no survivin protein was expressed 
after the second day (Fig. 3).
Expression change in survivin mRNA caused by oxaliplatin
The RT-PCR method was used to measure the expression of 
the total survivin mRNA and of each variant of mRNA. For 
the onset of survivin mRNA in variant forms caused by the 
primers, each specific primer was used and showed a single 
RT-PCR band. This showed that each primer was appropriate 
in testing the onset of variant mRNA (Fig. 4). When compared 
with the control group without oxaliplatin, survivin wild-type 
mRNA showed reduced expression on the second day, but the 
expression increased again on day 3. Survivin-2B variant did 
not show any change on the first day, but showed reduced ex-
pression throughout days two and three. Survivin-ΔEx3 vari-
ant had reduced expression from the first day, in spite of its 
small amount (Fig. 5).
Measurement through flow cytometry of the change in the 
cell cycle caused by oxaliplatin 
After treatment with oxaliplatin for 24 hours and 48 hours, 
the cell-cycle changes in both the control group and the treated 
group were measured using flowcytometry. After 24 hours of 
culture, the percent of subG1 phase (representing the death of 
a cell) cells increased from 12.47% to 22.39%. After 48 hours, 
it increased from 9.47% to 28.21%. The percent of cells in the 
G0-G1 (gap 0 and gap1) phase decreased from 82.56% to 67.65% 
after 24 hours and from 80.50% to 59.76% after 48 hours. The 
S (DNA synthesis) phase fraction increased from 5.10% to 
5.66% after 24 hours, reduced from 9.32% to 5.25% after 48 
hours, and showed a slight increase after that. The percent of 
cells in the G2 (gap 2) phase increased from 0.25% to 4.61% 
after 24 hours and from 0.36% to 5.04% after 48 hours (Fig. 6).
Change in the intracellular location of survivin caused by 
oxaliplatin
When the sample is cultured without oxaliplatin, the survivin 
protein often appears to be located in the cytoplasm because 
the contractile ring or microtubule areas are lightly dyed (Figs. 
7A-C, 8A, 9A). After culturing the control group for 24 hours, 
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Fig. 5. Survivin variant mRNA expression in HCT116 colon cancer 
cells after incubation with 2.0 μM of oxaliplatin for 1-3 days.  
Fig. 6. Measurement of the cell-cycle phase by using flowcytometry after incubation with 2.0 μM of oxaliplatin for 24 and 48 hours. 
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the protein is thought to be located in the chromosomes or 
the microtubule because it gets dyed with the chromosomes 
during the mid-phase of mitosis (Figs. 7D-F, 8B). It gets dyed 
lightly in the cytoplasm after 48 hours of culture and is thought 
Fig. 8. Intracellular localization change of survivin after incubation for 24 hours without or w 2.0 μM of oxaliplatin.
A B C
Control 24 hr without oxaliplatin 24 hr with oxaliplatin
Fig. 7. Intracellular localization change 
of survivin after incubation with 2.0 μM 
of oxaliplatin. HCT116 colon cancer cells 
are stained with DAPI (A, D, G, J, M), 
survivin (B, E, H, K, N), and merge (C, F, 
I, L, O). We cultured the HCT116 cells 
for a control (A-C), without oxaliplatin 
for 24 hours (D-F) and 48 hours (G-I), 
and with 2.0 μM of oxaliplatin for 24 
hours (J-L) and 48 hours (M-O). 
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to be located in the contractile ring or microtubule during cy-
tokinesis (Figs. 7G-I, 9B). However, after treatment with oxali-
platin for 24 hours and 48 hours, only the cytoplasm gets lightly 
dyed, and the survivin protein’s intracellular change of location 
is thought to be caused by oxaliplatin (Figs. 7J-O, 8C, 9C).
DISCUSSION
Survivin is one of the human IAP homologues, and it belongs 
to the inhibitor of apoptosis protein (IAP) family [9]. Every 
single IAP has one or more baculovirus IAP repeat (BIR), and 
a BIR consists of approximately 70 amino acids [10]. Eight 
human IAPs, c-IAP1, c-IAP2, XIAP, NAIP, survivin, apollon, 
ML-IAP/livin, ILP-2, have been found [11]. Survivin is located 
at 17q25, consists of 142 amino acids, and has the size of 16.5 
kDa. Survivin has the structure of a long alpha-helix, does not 
have the RING finger, and has a single BIR area structurally. 
The long alpha-helix structure of the carboxyl terminal in sur-
vivin interacts with the microtubules [12]. A gene of the sur-
vivin has 4 main axons (1, 2, 3, and 4) and 2 hidden axons (2B 
and 3B). Accordingly, there are three different variants of sur-
vivin, survivin-2B, survivin-ΔEx3, and survivin-3B. Survivin-
ΔEx3 is a variant with the loss of the third axon, and survivin-
2B is a variant with an additional short axon called intron 2.
The expression of survivin is controlled by the cell cycle and 
is related to the control of cell death and cell division [13]. 
According to recent studies, survivin is also found in a nor-
mal colon mucosa and a proliferative polyp [14]. According 
to the existing research, survivin expression among patients 
with cancer is reported to be a bad clinical sign with an unfa-
vorable prognosis for progression of the illness and a reduced 
survival rate. Thus, survivin detection in urine for patients 
with bladder cancer is considered to be a sign for an unfavor-
able prognosis, and a urine test for survivin detection is ac-
credited as a prognosis-predicting factor bn[15, 16]. In stom-
ach cancer, the expression of survivin was reported to indicate 
an unfavorable prognosis and reduced cell death [17]. How-
ever, other studies reported that although expression of sur-
vivin within the nucleus is related to a favorable prognosis, 
expression within the cytoplasm is not related with an unfa-
vorable prognosis [18]. It was also reported that positive nu-
cleus dyeing in hepatic cancer is related to proliferation [19]. 
Expression of survivin in colorectal cancer is related to the 
onset of bcl-2, tumor growth, and low survival rate. It is also 
related to the response in chem otherapy of patients with rec-
tal cancer [20-25]. Among survivin variants, survivin-ΔEx3 is 
known to have relationships with apoptosis, but the reduction 
of survivin-2B onset is known to have relationships with the 
progress of cancer in stomach cancer, colon cancer, and many 
other types of cancer [8, 26-29].
Oxaliplatin is a primary anticancer drug that is used in pa-
tients with stage 3 or higher colon cancer or metastatic colorec-
tal cancer. It is in the family of 3rd-generation platinum com-
pound anticancer drugs, but does not have nephrotoxicity re-
lated to cisplatin, has less myelosuppression related to carbo-
platin, and has a higher response rate to colon cancer when 
compared to cisplatin. However, there is not much known about 
the precise acting mechanism of oxaliplatin, and recent stud-
ies have reported the cytotoxicity by repressing survivin ex-
pression to be one of the acting mechanism [5-7].
This research observed that survivin protein expression was 
reduced one day after the oxaliplatin was added to the colon 
cancer cell strain. The expression started to decrease after the 
first day and was almost completely repressed after the second 
day. Also, according to the RT-PCR measurements of the sur-
vivin variant expression rate with its special primer, wild-type 
survivin mRNA showed decreased expression after the second 
day, but showed a recovery after the third day. Among survivin 
variants, the expression of survivin-2B (known for not repress-
ing cell death) was reduced after the second day and kept on 
decreasing after the third day. The survivin-ΔEx3 variant (with 
missing 3rd axon) showed reduced expression after the first 
day and continued to show a decrease even after the third day. 
The total survivin mRNA expression was decreased by oxali-
Fig. 9. Intracellular localization change of survivin after incubation for 48 hours without or w/2.0 μM of oxaliplatin.
A B C
Control 48 hr without oxaliplatin 48 hr with oxaliplatinJournal of the Korean Society of
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platin, but recovered again. On the other hand, expression of 
the survivin variant not related to apoptosis decreased contin-
uously.
Even in the cell-cycle analysis done by using flowcytometry, 
cells treated with oxaliplatin and cultured for 24 hours and 48 
hours had increased cell death of approximately 10% to 22-
28% compared to the control sample. This shows that the ex-
pression of survivin recovers on the third day, but survivin-
ΔEx3, which represses apoptosis, decreases continuously, and 
apoptosis occurs continuously. The reason for reduced expres-
sion of survivin-2B (with almost no repression of apoptosis) 
is thought to be the dislocation of the survivin-2B in the G2/M 
phase, which causes a mitotic catastrophe by disturbing bipo-
lar spindle fiber formation during mitosis.
The results of dying DAPI and survivin after treating with 
oxaliplatin showed reduced survivin expression within the 
cytoplasm when compared with the control group. Also, sur-
vivin does not appear in microtubules or chromosomes dur-
ing mitosis, which is thought to cause disruption in cell divi-
sion. More research is necessary in order to determine which 
variant survivin is found within either the nucleus or the cy-
toplasm and which causes not only cell death but also mitotic 
catastrophe.
According to our results, mechanisms of oxaliplatin include 
repression of the onset of survivin, cell death, and lack of for-
mation in microtubules or contractile rings during the cell 
cycle. Therefore, as reported by Fortugno [3], it is thought to 
disturb the formation of bipolar spindle fibers during mitosis.
Oxaliplatin’s acting mechanism not only represses the onset 
of survivin in the HCT116 colon cancer cell strain but also 
causes apoptosis by changing the location of expression within 
the cell. Also, it fails to settle in the microtubules, causing dis-
order in mitotic recombination that will show cytotoxicity.
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